OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report and Accounts for the year ended 31 December 2025

Company Registration Number: 04370087 Registered Charity Number (England and Wales): 1091708 Registered Charity Number (Scotland): SC042612

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Contents

Legal and Administrative Information .............................................................................................................. 3 From the Chief Executive and Chair of the Board of Trustees ......................................................................... 4 Aims and Vision ................................................................................................................................................ 7 Objectives and Activities .................................................................................................................................. 7 Goals 2025 ........................................................................................................................................................ 8 Achievements and Performance .................................................................................................................... 11 Towards 2030 – Closing the Gaps in Gynaecological Cancer ......................................................................... 26 Structure, Governance and Management ...................................................................................................... 28 Financial Review 2025 .................................................................................................................................... 32 Statement of Trustees’ Responsibilities ......................................................................................................... 33 Independent Auditor’s Report to the Trustees of Gynaecology Cancer Research Fund ............................... 35 Notes to the Financial Statements ................................................................................................................. 43

2

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Legal and Administrative Information

Charity Name

Gynaecology Cancer Research Fund – operating as ‘The Eve Appeal’

Trustees

Tamara Box (Appointed 01/07/2020) (Chair of Trustees effective 08/02/2024) Helen Byrne (Appointed 05/02/2025) Dr Christine Ekechi (Appointed 26/10/2020) Prof Ian Jacobs (Appointed 29/05/2022) Sarah Morris (Appointed 19/12/2019) Marion O’Hara (Appointed 27/10/2021) Prof Adam Rosenthal (Appointed 26/10/2020) Sally Bailey (Appointed 18/10/2023) Emma Dean (Appointed 18/10/2023)

Chief Executive

Athena Lamnisos

Registered Charity Number (England and Wales): 1091708 Registered Charity Number (Scotland): SC042612 Registered Company Number: 04370087

Principal Office of Charity and Registered Office

The Eve Appeal, 10-18 Union Street, London, SE1 1SZ

Auditor

Moore Kingston Smith LLP, 6th Floor, 9 Appold Street, London, EC2A 2AP

Bankers

CAF Bank Limited, 25 Kings Hill Avenue, Kings Hill, West Malling, Kent, ME19 4JQ

Unity Trust Bank plc, PO Box 7193, Planetary Road, Willenhall, WV1 9DG

Solicitors

Bates Wells, 10 Queen Street Place, London, EC4R 1BE

Reed Smith, Broadgate Tower, 20 Primrose St, London EC2A 2RS

3

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

From the Chief Executive and Chair of the Board of Trustees

Over the course of 2025, Eve maintained our ambition to accelerate progress on early diagnosis and prevention by investing in medical research and education. This is reflected in the funding of our third research fellow who will focus her programme on looking at new ways of diagnosing a type of womb cancer with the worst outcomes and that disproportionately affects Black women and people with gynae organs. We are excited to award this funding to the team at the world class Manchester University Cancer Research Centre and to fund this programme in partnership with North West Cancer Research. The power of collaboration to double the investment in our gynaecological fellowships programme is something we are very proud of.

We are delighted to have launched a new research award for seed funding innovative research programmes. We were overwhelmed by the quality and range of applications in the first year of this award stream and are really proud to have funded seven projects in Southampton, London and Birmingham, amongst others.

During 2025, we concluded our funding for a longstanding research programme led by the Department for Women’s Health at UCL. This team has been funded by Eve since 2014 to support the ambitious, multistranded FORECEE (4C) programme which aimed to develop a test for four different types of cancer. We are delighted with the progress that this research has made and one test – to diagnose womb cancer – is currently part of a National Institute for Health Research programme, trialling the test in NHS clinical settings. It’s thrilling for the team, and for our supporters who have been on this journey with us, to have research move from the lab bench to the clinic.

We have stepped up our policy work: to evidence how those affected by gynae cancers are often failed, to provide expert insight into what needs to change, and to outline how change can happen. We are contributing insights to a range of national and international forums and policy programmes including hosting an event for MPs during Ovarian Cancer Awareness Month. We continue to contribute to a range of policy work to support the Cervical Cancer Elimination Plan. This work is focused on reaching the ambitious goal to eliminate cervical cancer in England by 2040. Alongside other charities, we have supported the introduction of the Rare Cancers Bill through the parliamentary process. MP Scott Arthur has led this work, and the Bill, due to become law in Spring 2026, will provide much needed support for research into rare cancers. A huge cause of celebration.

While important progress has been made across gynaecological cancer awareness, our work and the contacts to our Ask Eve nurse information service tell us that they are still being overlooked and that we need to continue our efforts on driving forward awareness on the signs, symptoms and risk factors of all five cancers. With this in mind, we have looked for sustainable solutions to providing the much-needed expert and evidence-based information which those affected by the gynaecological cancers need. We secured funding for the scoping and development of an AI tool which will act as a new part of our information service and help build capacity in our Ask Eve team to spend more time with the patients who have the most complex information needs. We hope to launch this tool later in 2026.

4

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Despite the challenging economic climate, we met our income targets and are grateful to our partners, donors and all those in our community who have supported us with generous donations and gifts in kind. The Eve team of expert, committed and ambitious staff, trustees, volunteers and advocates have made all our success possible. These are unprecedented times, but a shift to prevention in healthcare won’t happen without all of us driving it forward. Our ambition and resolve remains: to invest in research, educate people about gynaecological cancers, offer expert information, and influence policy nationally and internationally. And it remains time critical.

As we come to the end of our three-year strategy in 2025, we reflected on what we achieved, the impact we have made, and where we need to focus our efforts moving forward. We have been through a rigorous and reflective process which has brought together the whole team – staff and trustees – to review where we want to see our impact over the next five years.

This collaborative and insightful process has resulted in a focused new organisational strategy where we feel confident that Eve can really shift the dial on the five gynaecological cancers.

We are in an exciting time in healthcare in the UK. A new NHS 10 Year Plan, a National Cancer Plan and a revised Women’s Health Strategy. A policy landscape and set of commitments in health where we are so heartened by both the commitment to prevention and the understanding that health inequities must be addressed in cancer if we are to make the progress we all want to see. We remain firmly focused on prevention and early diagnosis and seeing a world where all gynaecological cancers are prevented or detected at an early stage.

Our 2025-2030 strategy will build on our momentum and impact but with a new focus on addressing the gaps which exist across the five gynaecological cancers. The strategy will continue to harness our partnerships and collaborations, new digital opportunities and our growing reach to focus on the gaps in research funding, in reaching the audiences who need us most and in gaining profile and awareness for these cancers.

All five gynaecological cancers are ‘rare’. They aren’t one of the cancers that most people have heard of and where awareness of signs, symptoms and risk factors is much higher. But rare shouldn’t mean unfair. Progress hasn’t been fast enough — or fair enough for the gynae cancers. Investment in research and in public education programmes has been too low. Access to trusted information is unequal. Screening and prevention programmes do not adequately address specific health inequalities and inequities. Too many gynae cancers are diagnosed late – often after either the patient or their GP hasn’t recognised the symptoms as a potential cancer, and in some cases, after visits to A&E.

Across research, innovation, and care pathways, these gaps continue to cost lives. This has to change. Addressing the gaps in awareness, research, and in reaching all the audiences that need us most is where we will be putting our focus, funding and efforts over the next five years.

We will build on our strengths, work in partnership to go further and faster, and speak with a strong, united voice to drive the change that’s needed. Our public awareness, information, policy and research programmes will all focus where they will have the greatest impact and start to close these gaps. We will hold ourselves accountable by learning and improving every step of the way.

5

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

We will do this guided by data, shaped by lived experience, and grounded in our commitment to equity, diversity and inclusion — because everyone deserves the same chance of early detection, prevention, and care.

We are ambitious because we have to be. Earlier detection saves lives. Prevention is better than a cure. Together, we can create a future where gynaecological cancers are no longer diagnosed too late — and no one is left behind.

Athena Lamnisos, Chief Executive Officer

Tamara Box, Chair of the Board of Trustees

6

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Public Benefit Statement

In reporting on the objectives and achievements of the Charity, the Trustees have given due regard to the Charity Commission guidance on public benefit under the Charities Act 2011. The Gynaecology Cancer Research Fund constitutes a public benefit entity as defined by FRS102.

Aims and Vision

The Eve Appeal (“Eve”) is the leading gynaecological cancers charity.

There are five gynae cancers, which are womb, ovarian, cervical, vulval and vaginal cancer.

The world-leading research that we fund is ambitious and challenging but our vision is simple: A world where all gynaecological cancers are prevented or detected at an earlier stage.

Our aim is to prevent gynae cancers from developing in the first place, but if they do develop, we want to make sure they’re detected early so more people survive their diagnosis.

To make our goals a reality, we fund research in four key areas: uncovering the causes of gynae cancers, predicting a person’s risk of developing them, identifying how people can reduce their risk, and improving their detection and diagnosis.

We educate people about gynae health, from knowing their anatomy, what’s normal and what’s not, and when to seek help. We aim to increase awareness of the signs and symptoms of gynae cancers and what people should do if they spot anything they’re worried about.

Through our Ask Eve nurse service, we answer people’s questions about their gynae health, gynae cancers and provide vital reassurance. This free, confidential and expert support is available over the phone, via email and through our website.

Objectives and Activities

Introduction

Originally founded as the Gynaecology Cancer Research Fund in 1984 by Professor Ian Jacobs, The Eve Appeal was established in 2002 to raise awareness and funds into the research of the five gynaecological cancers: womb, ovarian, cervical, vulval and vaginal.

Every day in the UK, 60 women and people with gynae organs are diagnosed with a gynaecological cancer and 21 will die. Improving these grim statistics will take targeted investment in preventative research, but only 5% of UK cancer research funding goes on prevention and a tiny percentage of the total on the gynaecological cancers. One in three people can’t name a gynae cancer and one in four have felt not listened to in a gynae health appointment.

Eve was set up to save lives by funding ground-breaking research; since 2015 we’ve awarded over £3m to research focused on developing new screening, risk prediction and early detection methods. The research we fund is ambitious and challenging, while our razor-sharp focus means our funding leverages further funding from other sources. Alongside research, we also educate people about the signs and symptoms of gynae cancers, break down taboos and stigma around gynae health, and offer free and confidential information and support through our Ask Eve nurse service, where anyone can ask any question about gynae health.

The case for investing in gynaecological cancer research has never been more needed. As a research charity, we are proud to have been able to continue our research impact by investing new funds this year and not pausing or reducing any previously awarded research funds.

7

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Gynaecology Cancer Research Fund, trading as The Eve Appeal, is a company limited by guarantee and a registered charity. In its memorandum and articles of association (last updated 2 February 2022), the Charity’s objects are outlined as follows:

Goals 2025

Our organisational strategy for 2025

Our plan is built around strategic pillars that provide clarity, consistency and focus across the charity.

8

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Invest in innovation and discovery

We will unlock new and better ways to understand gynae cancer, through seed-funding innovation and moonshot research programmes. We will explore new avenues to fund our researchers, including commercial opportunities that arise from research. We will streamline the way we work and engage to help achieve our mission. A specific focus will be in supporting a womb cancer detection test, which has resulted from Eve funded research, being evaluated and moving into mainstream healthcare.

Engage and translate

We will accelerate our research findings into clinical practice, by sharing impact with the broadest range of policy, public, academic, lived-experience and clinical stakeholders. We will seek out those who need access to our health information and ensure it is shared in a way that is accessible and relevant to them. We will be investing in our ‘Eve Voices’ network of clinical, research and experts by lived experience during the year.

Drive support for our vision through collaboration

We will work across disciplines, across boundaries and connect in meaningful ways with all of our new and existing stakeholders, with the aim of raising the funds necessary to achieve our mission. Building our research co-funding across the charity sector and with other partners will be our focus.

Influence the new NHS 10 Year Plan

Making prevention and early detection central to delivery and ensure that we can support the development and implementation of delivery so that it reaches all parts of the community.

Priorities & Plans

The Eve team have made excellent progress against the action plans in the 3-year strategy. The following actions have been identified to ensure we meet the ambitious targets set two years ago:

Research and Advocacy

9

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Ask Eve

Outreach & Awareness

10

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Achievements and Performance

Research

In the final year of our three-year strategy, we have made significant progress on our objectives set in 2023:

Establish Eve Fellowship Programme – supporting early career researchers and engaging the patient voice in review

With limited funding, and uncertain pathways, the challenges for researchers working in gynaecological cancer are numerous. In 2023, our Board of Trustees agreed to continue our legacy of investing in the next generation of gynaecological cancer research leaders through a fellowship scheme. The aim was to attract and retain researchers in the field, by providing substantial financial assistance, resources, network, support and opportunities.

In 2025, we continued our successful partnership with North West Cancer Research and launched the third fellowship call. This round was open to research across the five gynaecological cancers. The scheme is now widely recognised internationally, and we had several excellent applicants. After rigorous review, we funded Dr Sarah Kitson’s project which focuses on understanding and preventing the most aggressive type of womb cancer, known as p53abn, which disproportionately affects Black women. The research aims to uncover how these cancers develop, identify those at higher risk, and explore whether early genetic changes or immune responses could be targeted for prevention.

Fund research across all five gynaecological cancers – active grants 2025

Eve is the leading UK charity funding research across the gynaecological cancers.

Rare Gynae Cancer Research Fund

Research on rare gynaecological cancers is limited, leading to later diagnoses and fewer treatment options. For patients with even rarer subtypes, there may be no active research at all. Recognising this need, Eve, supported by dedicated donors impacted by these cancers, now supports four pioneering projects to deepen understanding and improve outcomes for those affected.

Advances in Early Detection for Vulval Cancer and Pre-cancerous Conditions

Professor Maria Kyrgiou’s team at Imperial College London is pioneering a new approach to diagnosing and treating vulval cancer. Vulval cancer is a rare form of cancer affecting around 1,400 women in the UK each year. Diagnosing and treating vulval cancer is challenging as symptoms can mimic other conditions and surgery often requires multiple procedures which causes significant physical and psychological impacts.

11

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Maria’s team is developing an innovative diagnostic technology called Laser-Assisted Rapid Evaporative Ionisation Mass Spectrometry (Laser-REIMS). This technology uses a laser to sample tissue, generating a vapor that can instantly identify whether the tissue is healthy or precancerous/cancerous. Initial studies using Laser-REIMS in other gynaecological cancers, like ovarian and cervical cancer, show promising results and Maria’s team aim to extend this technology to vulval cancer.

By identifying affected areas in real time, this approach could reduce the need for repeat surgeries, minimise the removal of healthy tissue and improve outcomes for patients by ensuring that cancerous tissues are completely removed in a single surgery. Their work has already received recognition, with Dr. Maria Paraskevaidi, a lead researcher, presenting findings at major international conferences and winning multiple awards.

New Research Focused on Understanding and Detecting Mucinous Ovarian Cancer

Mucinous ovarian cancer is a rare and hard-to-treat type of ovarian cancer, accounting for only 2- 3% of ovarian cancer cases. Professor Sudha Sundar and her team at the University of Birmingham are investigating five specific hormone markers they identified as being linked to mucinous ovarian cancer. They will use “3D organoids” — mini tumour replicas grown from actual cancer cells — to help mimic real tumour behaviour in the lab.

This project is co-funded by the Birmingham Women’s Global Health Research Programme. It has also gained matched funding, allowing the team to expand their research collaborations nationally and internationally. The team has worked with diverse communities to make this research accessible, translating information into multiple languages and engaging with patients directly. Through this innovative approach, Sudha and her team are working to uncover new insights into mucinous ovarian cancer that could not only improve detection but also explore possible treatment options and make a real difference for women with this disease.

Research on Vulval Cancer Aims to Identify Risk Factors for Women with Lichen Sclerosus

Many women with vulval cancer also have a noncancerous skin condition called lichen sclerosus, which causes persistent inflammation and affects the vulva and anal area. Although only a small percentage (5%) of those with lichen sclerosus go on to develop vulval cancer, the reasons why some do and some don’t remain unknown.

Dr Jason Yap was originally awarded this grant, but it has been transferred to Dr Rachel Pounds, also at the University of Birmingham. She will examine whether specific genetic changes, or alterations, in cells could explain why vulval cancer develops in some women with lichen sclerosus. Her team will analyse biopsies from women with lichen sclerosus and those with both lichen sclerosus and vulval cancer to look for these changes. By identifying any patterns, Rachel hopes to uncover who may be at higher risk, allowing doctors to better monitor and support those individuals. For those at low risk, it could mean less frequent check-ups, which could ease anxiety and improve their quality of life.

New Research to Improve Diagnosis of Uterine Sarcomas

Uterine sarcomas are a rare and aggressive type of cancer that affects the womb. They account for around 3 in every 100 womb cancers and are challenging to diagnose accurately because they share many symptoms and imaging features with common, non-cancerous growths called fibroids. Currently, only about one-third of uterine sarcomas can be detected through standard biopsies of the womb lining. This can lead to delayed diagnosis, which may worsen outcomes for affected women.

Dr Esther Moss and her team at the University of Leicester are developing a blood test to help identify uterine sarcomas early and reliably. This test will be based on circulating tumour DNA

12

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

(ctDNA) – tiny fragments of DNA shed by cancer cells into the bloodstream. This project is particularly important for Black women, who are at higher risk of both fibroids and uterine sarcomas. Early and accurate diagnosis will allow for more tailored and safer treatment, improving outcomes for women with this rare type of cancer.

The Endometrial Cancer Audit

Building on our leadership in 2024, The Eve Appeal played a central role in progressing the Endometrial Cancer Audit pilot by convening key partners and providing vital funding support. Working in collaboration with the British Gynaecological Cancer Society, the British Association of Gynaecological Pathologists, and Peaches Womb Cancer Trust, the pilot has begun to generate important insights into the diagnosis, treatment, and outcomes of womb cancer across the UK. This work marks a significant step toward addressing variation in care, improving data collection, and strengthening the case for a fully commissioned, publicly funded national audit—helping to ensure more consistent and equitable care for all women and people with gynae organs affected by womb cancer. Helen Hyndman MBE from Eve continues to represent the lived experience voice on the steering committee.

Support our Heritage Core Programmes

Following several years of strategic support, a final set of research grants are being awarded to Professor Martin Widschwendter’s team at University College London to ensure the continued momentum of his Eve-supported portfolio of research as he works to secure long-term funding from other sources.

This year, strong progress has been made across several key studies. The Lynch Syndrome pilot, co-funded with Cancer Research UK, successfully demonstrated the feasibility of using the WIDqEC test for self-sampling in high-risk women, with all participant samples analysed and additional data used to refine the underlying algorithm. Alongside this, work to better understand how womb cancer develops in women with Lynch Syndrome is now well underway, with tissue samples prepared for detailed genetic analysis.

The EPI-SURE study, evaluating the performance of the WID-qEC test in Black women in the UK, has recruited over 300 participants to date, with further recruitment ongoing to strengthen findings.

Together, these studies represent important steps toward ensuring that innovative, less invasive early detection tools like WID-qEC are effective, equitable, and accessible for everyone at risk of womb cancer.

13

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

New grants

The Eve Appeal launched its Small Grants Scheme to support innovative, early-stage research ideas that have the potential to improve the prevention, detection, and treatment of gynaecological cancers. Designed to address gaps in funding for pilot and feasibility studies, the scheme enables researchers to generate the critical data needed to unlock larger-scale funding and accelerate progress in gynae cancer research. In 2025, four promising projects were awarded funding:

14

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Strengthening and Supporting the Research Advisory Committee

The Research Advisory Committee is an external group of research experts and people with lived experience who advise the Board of Trustees and the Senior Management Team on research matters at the charity, including the following responsibilities:

The Research Committee – which is a Board sub-committee - continues to work effectively and fulfils a number of important functions at Eve. This includes research strategy and planning; providing assurance about the peer and Research Advisory Committee review process (including handling any challenges or conflicts of interest that arise); scrutiny of research project budgets, overseeing research financial commitments and managing risk and associated mitigations arising from research activity.

As members of the Association of Medical Research Charities, Eve is audited every five years on research process and governance, and the audit took place in 2025.

The charity also undertook the process of updating the Research Strategy, as the current strategy was from 2018 – 2025. This work started with extensive stakeholder consultation, through surveys and one-to-one consultations with key members of the Eve community. We focused on building on our existing strengths while identifying key gaps in prevention, early detection, prevention and equitable access to care. Through this engagement with researchers, clinicians, and patient communities, the updated strategy will guide future investment, strengthen collaborations, and ensure our research continues to deliver meaningful impact.

Capture and Share Impact of Research Activity Across the Organisation

In 2025, Eve continued to strengthen how it captures and shares the impact of its research portfolio. Working closely with funded researchers and partners, we systematically gathered outcomes across studies, including publications, clinical progress, recruitment achievements, and patient-reported insights. This was complemented by the development of accessible case studies and plain-language summaries developed for our communication channels, to ensure findings could be understood beyond academic audiences. Impact was shared through the charity’s annual report, website, newsletters, and stakeholder communications, as well as presentations at conferences and events. Together, these activities helped demonstrate the real-world value of our research investment and ensured that learning is disseminated to patients, clinicians, funders, and the wider public.

15

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Ask Eve – Nurse-Led Information Service

Our Ask Eve service continues to be an essential service for anyone concerned about their gynaecological health. Ask Eve is vital to raising awareness of signs and symptoms, empowering and supporting early diagnosis, encouraging preventative action for those at risk, and supporting those diagnosed and their loved ones at all stages of the pathway and beyond. We also provide information to health and social care professionals who have questions about patients under their care, enabling them to offer correct, evidence-based information and guidance.

The ongoing NHS pressures, closer working relationships with NHS service providers, collaboration with other charities and organisations alongside the increased awareness of The Eve Appeal and Ask Eve has led to a continuous and rapid increase in demand for Ask Eve over the last 12 months. There has been a 48% increase in cervical related queries, 57% increase in other contacts alongside a significant increase in the complexity and acuity of contacts. Many people concerned about symptoms and experiencing significant delays in appointments, investigations and treatment contact Ask Eve for information and support. Despite this huge increase, Ask Eve has maintained a 100% “extremely satisfied” rating from service users.

Ask Eve is accessed by phone, email, on-line contact form, or Teams calls under specific circumstances. Ask Eve continues to offer immediate access to translation services, BSL and Easy Read materials to support accessibility.

Service users value the opportunity to talk through their concerns in detail and receive the individualised information and support they need, as well as empowerment so they can advocate for their own gynae health. The average time spent on a simple phone or email response is 15 minutes, one and a half times as long as a GP consultation. The average time spent on a complex phone or email response is 46 minutes, four times longer than a GP appointment.

An AI assisted heath information system, Ask Eve Assist, has been developed, piloted with users and evaluated, to enhance capacity, improve accessibility and ensure sustainability. Ask Eve Assist provides automated responses to routine, low-risk queries, using only PIF TICK accredited content from our website, freeing up nursing capacity for complex and clinically urgent cases. Comprehensive safeguarding and escalation protocols are in place and design has been aligned with Web Content Accessibility Guidelines. Ask Eve Assist provides 24/7 access, supporting users who cannot reach Ask Eve during working hours, those with low confidence navigating the healthcare system, and individuals facing accessibility barriers. Official launch of Ask Eve Assist is planned for later in 2026.

We have also participated in several key pieces of work which include:

16

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Information and Awareness

Information and awareness is a key pillar of our work at Eve. Across the whole year our gynae health information webpages had over 325,500 views. Our social posts, which contain vital gynae health information, were seen nearly 11,588,000 times. We also ran ads across social media and Google to try increase awareness of gynae cancers, these were seen over 1,495,000 times.

Eve was mentioned in the media 1,700 times in 2025, 73% more than in 2024. The titles we were mentioned in have a potential reach of 18 billion. These articles shared key gynae health information, how people can get support from our Ask Eve Nurses, and commented on key stories in the news. Key outlets include BBC online, Guardian Online, Mail Online, The independent, Express UK, AOL, Yahoo! News UK & Ireland, The Sun Online, The Telegraph, MSN UK, Daily Mail Online and Mirror Online.

2025 Public Awareness and Education Campaigns

Cervical Cancer Prevention Week

This year we set out to provide practical advice and support to help make cervical screening easier and more accessible, empowering more people to attend their appointments with confidence. Across the week our organic social media channels, Meta adverts, Google Pay per click ads, and email reached over 714,000 people. Our Cervical Cancer Prevention Week webpage, including tips, received nearly 8,500 views.

We also were able to reach 6.5 million people through public advertising across cities including London, Liverpool, Birmingham, Sheffield, Cardiff, Swansea and Hull. We received 80 pieces of media coverage including BBC Online, BBC London News Today, Independent, Telegraph, The Sun, i News, BBC Radio 2, 4 and 5 Live, with an estimated reach of 3.36 billion.

Ask Eve received a 3208% increase in cervical related contacts to Ask Eve compared to Cervical Cancer Prevention Week in 2024.

Ovarian Cancer Awareness Month

This Ovarian Cancer Awareness Month we re-launched our rare ovarian cancer webpages and shared information on ovarian cancer- its symptoms, risk factors and the rarer forms. Our organic social media reached over 203,300 on Instagram and Facebook.

Get Lippy Campaign

This Get Lippy we shared our tips for gynae health appointments. Our YouGov survey found that 1 in 3 women had put off getting gynae symptoms checked out. 1 in 3 said they felt nervous or uncomfortable talking about gynae health with a doctor and 1 in 4 said they have felt embarrassed. We worked with a host of ambassadors to spread the message.

Nearly 2.45M people viewed our content organically across our social media platforms. We received 44 pieces of media coverage with an estimated 378 million in reach. Coverage included ITV News, Channel 5 News, Yahoo, The Independent, The Sun, Daily Mail, Telegraph, BBC online, Standard, BBC 5 Live, Industry Beauty, The Mirror, GB News, Wales Online, PopSugar.

Cervical Screening Awareness Week

June was a busy period in the context of the NHS England and Department of Health and Social Care announcements around changes to the national Cervical Screening Programme. There was widespread misunderstandings and anxiety about the changes. We commissioned a YouGov survey to help us talk about the recently announced cervical screening interval changes, with a hope of easing people’s worries and concerns about the changes. We were in the media 200 times over the period, with an estimated reach of almost 777 million people. Over 3,500 people visited our campaign page and tips for making cervical screening more comfortable. Our information was reached nearly 190,500 times on our organic social media channels, Meta adverts, and email.

17

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Gynaecological Cancer Awareness Month

This Gynae Cancer Awareness Month we ran a campaign promoting the risk factors of the five gynae cancers, including how to understand and reduce your own personal risk. We received 1,197,552 organic views on our social media channels.

Outreach

Following our 2023 pilot outreach programme with south Asian communities in London, Birmingham and Manchester and our 2024 pilot reaching Black communities in the UK, we continued to develop and deliver to these key target groups in 2025. 20 awareness sessions were delivered between September and December 2025, reaching a total of 106 women from Black and south Asian communities with key information on the five gynae cancers.

Our outreach sessions were delivered in partnership with trusted local organisations and community groups. Where possible, the sessions were led by medical experts, who work across women’s health and gynaecology and from the community, ensuring sessions were culturally sensitive and trusted. We offered translated information in 17 key languages and three of the sessions were delivered with an interpreter. The percentage of contacts to our Ask Eve service increased from 13% to 16% in south Asian communities and 10% to 11% in Black communities.

From the south Asian community outreach sessions, the average rating in self-reported knowledge rose from 2.7 points out of six to 5.5 points out of six (103.7% increase).

From the Black community outreach sessions, the average rating in self-reported knowledge rose from 2.9 points out of five to 4.8 points out of five (65.5% increase).

Some feedback was:

18

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

North East London Outreach Programme - You Need to Know

We previously partnered with North East London Cancer Alliance to raise awareness of the key symptoms of womb cancer by delivering a local campaign and 12 community educational events with 250 attendees. This year (2025), the campaign gained national recognition and the evaluation results were published in the British Medical Journal which reflected the importance of communityled work and improved awareness and confidence in seeking help.

In 2025 we launched phase two focusing on recognising ovarian cancer symptoms and promoting early diagnosis, which can save lives. The second phase was launched at local nail salons, offering the opportunity to engage with local women, share vital resources, and invite them to receive a limited number of free, signature You Need to Know manicures, designed to spark conversations and raise awareness. There were eight pieces of news coverage, including being covered on BBC London, with a combined reach of 50.5 million. The new presentations were developed by our health information team, these were lay reviewed by five people from the local community. We delivered 11 information sessions in the local community across eight boroughs reaching 125 people.

Gypsy, Roma and Traveller community sessions

We delivered two cervical cancer prevention workshops online for Gypsy, Roma and Traveller community champions in North East London. These sessions were sense checked with community health champions and community organisations (including Roma Support and Friends, Families and Travellers) to address specific barriers. These healthcare champions will be raising awareness in their communities. These sessions were organised and funded by the North East London Cancer Alliance.

Feedback from Roma Support Group:

19

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

South East London Cancer Alliance

We delivered seven sessions (one in each borough) across South East London focusing on womb cancer. We delivered a further three sessions on all five gynae cancers, with a focus on womb and ovarian based on the You Need to Know sessions.

Liverpool and Merseyside

In 2025 we delivered three sessions in partnership with NHS Cheshire and Merseyside Cancer Alliance and Improving Me, a Women's Health and Maternity Programme based in the area. In total, we ran two in person sessions and one online, to a total of 74 women.

Other Health Information Sessions in the Community

We delivered an LGBT inclusive HPV awareness session for Societee Noir, a community group of women, trans women and Femme leaning non-binary persons of colour.

We delivered an HPV and cervical screening awareness session to Polish women with the House of Polish and European Community.

The average rating in self-reported knowledge post session was 5.7 points out of six. Participants rated the session as ‘easy to understand’ and when asked what they liked about the session said that it had ‘good visuals’.

20

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Health information

We know that not having access to appropriate information is one of the barriers preventing underserved communities accessing timely healthcare, leading to a later diagnosis of gynae cancer and sadly, worse outcomes. We are a PIF TICK approved health information provider and have a clear focus on addressing health inequalities by providing engaging and easy to understand information for the people who need it most. In 2025 we launched 14 new health information pages on our website, across rare ovarian cancer, prevention, reducing your risk, information for health care professionals and a new cervical screening leaflet.

Rare ovarian cancer pages

We re-launched five rare ovarian cancer pages: clear cell ovarian cancer, small cell ovarian cancer, mucinous ovarian cancer, germ cell ovarian cancer and sex cord stomal cancer. These new pages received 1203 total views between March-December 2025.

Prevention pages

In March 2025 we also launched five preventing cancer pages: information on cervical screening results, LLETZ, colposcopy, and the HPV vaccination. These new pages received 11,431 total views between March-December 2025. We also updated our HPV page which received 4,804 views across the whole of 2025.

Healthcare professional training pages

In October 2025 we launched three Health Care Professional pages to give advice and training on improving screening uptake, supporting patients and answering their questions on HPV and colposcopy. These new pages received 321 views between October-December 2025 (178 HPV, 93 screening uptake, 50 colposcopy).

Reducing your risk

In September 2025, as part of our Gynae Cancer Awareness Month campaign we launched a new page on ‘reducing your risk’ including information on risk factors linked to each gynae cancer.

Cervical screening leaflet

We created a new cervical screening leaflet which was launched in June 2025. This leaflet was downloaded 144 times between June-December 2025.

Fundraising

From the General Public

We are overwhelmed by the continued support of all those who choose to donate and fundraise towards our work during the year and the difference they are making.

Whether fundraising in their community, running marathons or donating in response to our appeals, generous people across the UK and beyond continued to pull together and do what they could to help stop gynaecological cancers before they start.

Gifts from the general public account for the vast majority of our income and so it is only thanks to these inspiring and generous individuals that we can fund world-class research, our cancer information service Ask Eve and our vital education work.

We are also touched by the incredible supporters who chose to include a gift to Eve in their Will. These gifts make a real and lasting difference that will benefit all those affected by gynaecological cancers for generations to come. It’s an incredible legacy to leave.

21

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

From Businesses

We are truly thankful for the ongoing support of our long-term corporate partners, including Tesco, Cosmetic Executive Women UK (CEW), League Manager's Association, Cisco, England and Wales Cricket Board - Women's Team and Saks Hair and Beauty Salons, who continue to support Eve in so many ways.

We are also incredibly grateful to all those businesses that chose to support us during 2025 as part of Get Lippy, and especially to Daish's and Boux Avenue who supported us as their Charity of the Year and to MSD UK, Hologic, BD and Roche for their ongoing partnerships.

From Trusts and Foundations

We would like to thank all Trusts who supported us during 2025 including The Peter Stebbings Memorial Charity, the PF Charitable Trust and especially St James' Place Charitable Foundation for their multi-year funding, bringing stability and security to our Ask Eve service.

Impact

Despite the many challenges of capturing our impact as a small medical research and advocacy charity, we continue to support real change – in transformative research discovery, clinical practice, accessing appropriate care, developing a broader understanding about gynaecological health, reaching those who are not supported, and in breaking down the barriers that women and people with gynae organs face managing their health.

Impact can be difficult to judge through numbers alone; success can mean a single call encouraging someone to attend a cervical screening appointment or feasibility funding to a smallscale research project.

Our relatively small research investments have enabled our researchers to leverage significant follow-on funds from national and international funding bodies. New awards made in the past 12 months provide the foundations of novel research that could make quicker diagnosis and ultimately improve outcomes. It is particularly gratifying for all of our stakeholders to see that riskier research, supported in the early days, has many years later led to important changes in clinical practice.

In 2025, Eve has demonstrated leadership in research support and advocacy, within the fields of gynaecological cancer and health.

Eve has played a role in helping to shape national policy, contributing to consultations such as the NHS 10-Year Plan and the National Cancer Plan, and actively participating in parliamentary events focused on ovarian cancer and broader gynae health issues. The involvement in the Rare Cancers Bill and the All-Party Parliamentary Groups on Sexual and Reproductive Health and Women’s Health underscores commitment to influencing legislative change. Eve has also led high-profile advocacy efforts, including chairing and speaking at international forums including Advancing Cervical Cancer Screenings (ACCESS), the international HPV congress (EUROGIN) and European Society of Gynaecological Oncology network of European patient advocacy groups (ENGAGe), and participating in major conferences such as the British Gynaecological Cancer Society Annual Scientific Meeting and presenting at the House of Lords showcase on NHS cancer innovation.

Eve has supported a wide range of research initiatives, from patient recruitment for genomic testing and survivorship studies to co-designing educational resources for womb cancer patients. Outreach visits started this year, and members of the Research Committee visited leading institutions including Imperial College London and Queen Mary University of London. These visits

22

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

strengthen collaboration between established and early career researchers and help to identify research priorities.

Eve has also contributed expert insights to industry-led sessions on cervical screening and AI in advocacy and has been recognised by organisations such as the Association of Medical Research Charities, where Vas James, The Head of Programmes was selected as an auditor for best practice in research governance. Through these activities, Eve continues to bridge the gap between research, policy, and lived experience, positioning the charity as a key driver of progress in gynaecological cancer prevention.

Eve has submitted two abstracts to academic journals and for presentation at EUROGIN and European Society of Gynaecological Oncology. One is on AI as a potential tool to manage increased gynaecological inquiries faced by a patient advocacy organisation in the UK, and the other on patient centred screening choices. Both are also being prepared for submitted for publication in relevant academic journals. These pieces of work are being supported with pro bono public affairs support and specific restricted funding.

Pioneering new ideas

Supporting early career researchers

Commitment to equality

23

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Driving change

The transformational power of a fellowship

A decade of progress: from discovery to NHS implementation

24

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Information and Awareness Impact

Year-on-year our impact and reach is continuing to grow thanks to our wonderful supporters and community. With hundreds of thousands of views to our website and millions of views across the media and our social media channels, Eve has become the ‘go-to’ source for honest, trusted, health information and support.

As we continue to grow our pool of information and work hard to get it to the people who need it most, we are grateful for the support of our partner organisations who help us reach their communities who currently face barriers to healthcare. From other charities, grass roots community organisations, faith groups, and our medical advocates, women and people affected by gynae cancers, ambassadors, and supporters - everyone who has helped worked with us or share our information is helping to realise our vision of a world where all gynaecological cancers are prevented or detected at an early stage.

Ask Eve Nurse Service Impact

The increasing number of contacts to Ask Eve and feedback obtained from our service user satisfaction questionnaire clearly demonstrates the impact and value. People are often signposted to us from GP’s, practice nurses, specialist gynae nurses, other health and social care professionals, charity organisations, family members and friends. Ask Eve is a reputable, trusted source for evidence based gynae health information and support. We continue to see an increase in the number of contacts from health and social care professionals requesting advice and guidance, further demonstrating our reputation as a trusted service.

With empathy, understanding, compassion and care, Ask Eve continues to help many facing extraordinary challenges, providing a lifeline to those concerned about gynae health and facing long waits for care. The testimonials from service users reflect this.

Ask Eve is meeting the needs of its users at a time when service demand is the highest it has ever been. The launch of Ask Eve Assist will enable the continued delivery of a high quality, accessible and inclusive service, reaching and meeting the needs of as many people as possible whilst continuing to demonstrate impact.

25

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

We are grateful to everyone who supports Ask Eve and contributes to its development and success. The added value of Ask Eve is summed up by one of our users:

Towards 2030 – Closing the Gaps in Gynaecological Cancer Strategic Planning

We carried out a full strategy review with Trustees and staff, and the Board approved our new strategy in November 2025. Our 2026-2032 strategy will guide us as we try close the gaps in gynaecological cancers. The new strategy includes:

Governance and People

Building a diverse, skilled, and connected board to guide The Eve Appeal confidently towards 2030, grounded in good governance, shared learning, and collaboration. Investing in, supporting, and developing our team so everyone can thrive, collaborate, and deliver their best work together.

Research

Building a world-leading research programme that funds innovation, grows talent, strengthens partnerships, and champions impact.

26

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Financial Management

Embedding best practice, improving systems, and ensuring finance is a strategic partner that supports scaling, planning, and effective delivery.

Communications & Outreach

Expanding the accessibility, reach and visibility of our communications and outreach efforts, through multi-channel engagement, community partnerships, education, and thought leadership.

Ask Eve

Strengthening Ask Eve and Ask Eve Assist to deliver high-quality, inclusive information, backed by strong systems, expert advisors, and partnerships across healthcare.

27

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Fundraising

Diversifying our portfolio, building lasting income resilience, growing overall income, strategically focussing our time.

Structure, Governance and Management

Organisational structure and decision making

The Charity is governed by a Board of Trustees who are members and also directors of the Charity for the purposes of the Companies Act. The Board sets the strategic direction of the Charity, ensuring that the charitable purposes of the Charity are met. Day-to-day running of the Charity is delegated by the Board to the Chief Executive Officer.

Eve considers each of the Trustees to be independent in character and judgement and understands that they have no relationships that are likely to affect, or could appear to affect, their judgements with regard to the Charity. Declarations of interest are required from new Trustees upon appointment and every meeting of the Board requires that any new interests are declared. No remuneration is provided except for reasonable travel and subsistence costs; in 2025 this figure was £0.

There are two Committees which make recommendations to the Board: The Finance & Audit Committee and the Research Committee.

The purpose of the Finance & Audit Committee is to ensure that a strategic approach is taken in the areas of finance, risk, audit, remuneration and other operational areas. The Finance & Audit Committee is comprised of at least four members, all of whom are Trustees, who give detailed consideration, on behalf of the Board, to these matters.

The Research Committee provides scientific research advice and works on the recommendations of the external Research Advisory Committee for new funding decisions. These recommendations are viewed in light of the charity’s mission, charitable objectives and financial position, and the committee makes recommendations and provides advice to the Board of Trustees.

The Charity had one 100% owned subsidiary company in the year. Eve Appeal Limited is a trading company that distributes its profits under Gift Aid to the Charity.

In 2021, in recognition of the Charity's support for key support programmes, the Principal Investigator, Professor Martin Widschwendter, gifted Eve shares in a company, Sola Diagnostics GMBH, which will be taking forward innovative diagnostic tests which are at an early stage of development. Any profits arising from the venture will be fed back into academic medical research programmes. In 2025 Sola Diagnostics GMBH had yet to make a profit.

28

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Trustee appointment, induction and training

Trustees are appointed in accordance with the Memorandum and Articles of Association, taking into account the benefits of appointing a person who is able, by virtue of his or her personal or professional qualifications and experience, to make a contribution to the pursuit of the objects or the management of the Charity.

Trustees and staff consider the skills gaps formed by departing Trustees and both openly advertise for and nominate appropriate individuals with skills to match before recommendation to Board for appointment. References are taken before appointment is formalised and prospective Trustees are then proposed and appointed at the AGM.

The Charity undertakes a comprehensive induction programme for all new Trustees, which includes induction materials relating to its purposes and finances, the powers and duties of the Trustees and information about day-to-day running of Eve. Key documents are provided, such as the Memorandum and Articles of Association, the Charity Commission’s Essential Trustee guide, up-to-date accounts, and minutes of the most recent Trustee meetings. Prospective Trustees may also attend relevant Trustee meetings as an observer as part of the induction process alongside introductions to key people and places. Trustees continue to be supported through ongoing training, with skills requirements regularly reviewed. We undertook a Trustees skills audit in the last quarter of 2025. This was led by a Trustee and supported by the CEO. The audit highted the priority areas for recruitment to best support the charity’s objectives and values and our commitment to addressing health inequalities and driving innovative and diverse thinking.

The Trustees who served in the period under review were: The Trustees who served in the period under review were:
Tamara Box (Appointed 01/07/2020) (Chair of Trustees effective
08/02/2024)
Sarah Clark (Resigned 04/02/2026)
Ian Drew (Resigned 05/02/2025)
Dr Christine Ekechi (Appointed 26/10/2020)
Prof Ian Jacobs (Appointed 29/05/2022)
Sarah Morris (Appointed 19/12/2019)
Marion O’Hara (Appointed 27/10/2021)
Cathy Pittham-Wiley (Resigned 04/02/2026)
Prof Adam Rosenthal (Appointed 26/10/2020)
Sally Bailey (Appointed 18/10/2023)
Dee Brecker (Resigned 23/01/2025)
Emma Dean (Appointed 18/10/2023)
Helen Byrne (Appointed 05/02/2025)

Declaration of Interests

All Trustees and staff are required to declare their interests, and any payments (including, but not limited to, benefits in kind such as gifts, hospitality shopping/travel concessions, preferential treatment, etc) received in connection with their role in Eve where such interests would, or might, conflict with, or otherwise influence their decision-making in respect of the Charity's activities.

29

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Research Advisory Committee

With thanks to all members of the Research Advisory Committee:

Name Occupation and Organisation Date of
appointment
Professor Emma Crosbie
(Chair)		 Professor of Gynaecological Oncology
Manchester University		 January 2024
Lead Gynae Oncology Clinical Nurse
Mrs Rhea Crighton Specialist Royal Devon University
Healthcare Trust		 January 2021
Lay/Community Representative
Dr Helen Howie Lay/Community Representative January 2021
Professor Sudha Sundar Professor of Gynaecological Cancer,
University of Birmingham		 June 2019
Emeritus Professor of Women’s Cancer
Professor Anne Lanceley Care, Institute for Women’s Health, June 2024
University College London
Senior Lecturer, Primary Care Cancer
Dr Garth Funston Research, Wolfson Institute of Population June 2024
Health, Queen Mary University of London
Honorary Professor, Institute of Cancer and
Professor Raji Ganesan Genomic Sciences, Birmingham University; June 2024
Consultant Gynaecological Pathologist
Professor of Ovarian Cancer Medicine in the
Professor James Brenton Department of Oncology, University of May 2025
Cambridge

Staff

A Senior Management Team comprising the Chief Executive, the Director of Fundraising, the Head of Finance and Head of Programmes allows for distribution of organisational responsibility and both staff and Trustees continue to be happy with the structure. The CEO has particular responsibility for issues relating to governance and for the financial management of the organisation.

Eve has 17 permanent members of staff and the Trustees record their appreciation of the efforts of the staff, who have again made an enormous contribution to the success of Eve and its mission during the year.

Volunteers and Advocates

Volunteers and advocates play an essential role in shaping and driving Eve’s mission. They share their personal experiences, support our research, review our health information, engage with the media, support fundraising and act as medical advocates across a range of activity. Their contributions ensure that our work remains patient-centred, impactful and far-reaching.

As we grow, we are committed to fostering a more structured and inclusive approach to volunteer engagement, recognising the vital role that Eve Voices play across our research, awareness and outreach efforts. By embedding meaningful involvement into our work, we aim to build a strong, empowered network that contributes to research, health education and advocacy in a way that benefits both the charity and those involved.

30

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

We are hugely proud of our many advocates and their passion and engagement in the charity. We are also proud of our support of these volunteers to date and the close community that we have fostered. We are working to build on this strong foundation and develop clear frameworks to support, train and recognise our volunteers, ensuring that their time and expertise are valued.

By strengthening our systems for engagement and impact measurement, we will continue to build a charity that not only listens to its community but thrives because of it. Our volunteers and advocates are the heart of our work, and their voices will shape the future of gynaecological cancer prevention and early detection.

Equity, Diversity and Inclusion

Equality, diversity and inclusion is at the heart of everything we do. Gynaecological cancers can have a negative impact on anyone’s life. That’s why we make sure our research, educational campaigns and free, expert information and advice are focused on helping everyone who could be affected by a gynaecological cancer.

We want to prevent every single case of gynaecological cancer possible. To do that we know that addressing health inequalities is central to our mission. We work with diverse communities across the UK to raise awareness of gynaecological cancers, to guide our research projects and our policy discussions.

We're unwavering in our commitment to foster an environment where equity is promoted, diversity is valued and celebrated, and everyone feels included. We are committed to preventing discrimination and achieving equality of opportunity. We believe everyone has the right to live free from abuse or neglect regardless of age, ability or disability, sex, race, religion, ethnic origin, sexual orientation, marital or gender status.

We do not discriminate on the grounds of domestic circumstances, educational or socialeconomic status, political affiliation, or trade union membership.

We're guided by our values and continuously learn and adapt to ensure EDI is embedded in everything we do. We invite all our partners, suppliers and supporters to join us in this work.

Safeguarding Policy

All staff and Trustees have been offered training. We have a safeguarding lead Trustee and a clear escalation process in place. Safeguarding issues and concerns are notified to the Board as part of the quarterly reporting process.

We are committed to creating and maintaining a safe and positive environment and an open, listening culture where people feel able to share concerns without fear of retribution.

We acknowledge that safeguarding is everybody's responsibility and are committed to preventing abuse and neglect through safeguarding the welfare of all adults involved.

We recognise that health, well-being, ability, disability and need for care and support can affect a person's resilience. We recognise that some people experience barriers, for example, to communication in raising concerns or seeking help. We recognise that these factors can vary at different points in people's lives.

Safeguarding actions taken are consistent with the principles of adult safeguarding, ensuring that any action taken is prompt, proportionate and that it includes and respects the voice of the adult concerned.

31

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Financial Review 2025

At December 2025 year end, we reported a surplus of £389,168 (2024: £470,402) in unrestricted reserves to carry forward into 2026. This surplus comprises funds of £189,168 above our agreed operating reserves level of £200,000.

In line with our ambitious programme we committed £243,011 for research grants. Ending 2025 with substantial unrestricted reserves places Eve in a position to meet our award ambitions.

In summary, we begin 2026 in a cautious but stable position with £389,168 in unrestricted funds. This leaves £189,168 in free reserves. Free reserves are the unrestricted funds balance minus the operating reserves level of £200,000. At the end of 2025 overall cash balance was £1,081,311.

Funding

Fundraising policy Section 162a of the Charities Act 2011 requires charities to make a statement regarding fundraising activities. The legislation defines fundraising as ‘soliciting or otherwise procuring money or other property for charitable purposes’. Such amounts receivable are presented in our accounts as ‘donations and voluntary income’.

We confirm that all solicitations are managed internally, without involvement of commercial participators or professional fundraisers or third parties. The day-to-day management of all income generation is delegated to the executive team, which is accountable to the Trustees. We have received no complaints in relation to fundraising activities.

Eve is funded principally by voluntary donations from individuals and community groups who continue to support our work and mission. Corporate sponsorship and donations also account for a significant proportion of our funding. Without this support we would not be able to operate and we are incredibly grateful for every penny that is donated.

Risk Management

The Trustees have assessed the major risks to which Eve is exposed and are satisfied that systems are established to mitigate the Charity’s exposure to those risks. These risks are detailed on the Risk Register for Eve, with information on the current practice and strategy used to mitigate the risk. The Register is reviewed quarterly by Trustees.

The current Risk Register pays particular attention to the risks around the current fundraising environment and the on-going economic crises on income and operations, research not reaching intended objectives, fundraising targets being missed, loss of key individuals, IT failure (including cyber security risk) and incorrect information being provided on a health issue.

The integrity of medical information provided by the Charity is managed by agreed expert and lay reviewed protocols, with Patient Information Forum approved processes.

A balanced portfolio of fundraising activity spreads risk to reduce any potential impact. Regular financial planning, including re-forecast of fundraising income and expenditure, ensures early interventions can be made.

32

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Reserves Policy

The 2025 annual review of the reserves policy determined that adjustments were required to the figure set in 2025 of £200,000. The figure is set by the Board as a target of holding £200,000 in free reserves. This target is based on the contingency for wind up funds, calculated to satisfy all the Charity liabilities in the event of closure. In real terms, £200,000 represents just under three months’ budgeted expenditure, excluding expenditure on research grants and restricted charitable activities.

We begin 2026 in a cautious but stable position with £389,168 in unrestricted funds. This leaves £189,168 in free reserves which is in addition to operating reserve level of £200,000.

The Board will continue to review the reserves policy annually to ensure it remains appropriate to the needs of the Charity in the context of the economic climate.

Going Concern

The Trustees have reviewed the Charity’s financial position, taking into account the levels of reserves, cash, committed income included in the accounts, future plans and its systems of financial and risk management. The Trustees believe that the Charity is well placed to manage operational and financial risks successfully. Accordingly, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operation for the foreseeable future and consider that there are no material uncertainties about the group’s ability to continue as a going concern.

Grant Making Policy

The policy of the Trustees is to fund world-class medical research that will make the biggest impact in saving lives from gynaecological cancers, including funding proof-of-principle work to enable the award of future funding. As a member of the Association of Medical Research Charities, we have developed a strategy and funding decision-making processes that meet strict awarding criteria and review, and recommendations are made by independent experts in the research field.

Statement of Trustees’ Responsibilities

The Trustees (who are also directors of Gynaecology Cancer Research Fund for the purposes of company law) are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company and charity law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable group for that period. In preparing these financial statements, the Trustees are required to:

33

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

The Trustees are responsible for keeping adequate and proper accounting records that are sufficient to show and explain the charitable company’s transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

On behalf of the board:

Tamara Box, Chair Date: 15/6/2026

34

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Independent Auditor’s Report to the Trustees of Gynaecology Cancer Research Fund

Opinion

We have audited the financial statements of Gynaecology Cancer Research Fund (‘the parent charitable company’) and its subsidiaries (the ‘group’) for the year ended 31 December 2025 which comprise the Group Statement of Financial Activities (including the Group Summary Income and Expenditure Account), the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’ (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other

35

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees’ annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2001 requires us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement set out on page 33 the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s Responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s

36

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence

37

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the Charity’s Trustees, as a body in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 part 8 of the Charities Act 2011.

38

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

James Saunders, FCCA, DCHA (Senior Statutory Auditor) for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

6[th] floor Date: 15/6/2026 9 Appold Street London EC3A 2AP

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

39

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Gynaecology Cancer Research Fund

Consolidated Statement of Financial Activities (incorporating an income and expenditure account) for the year ended 31 December 2025

Notes
Income
Donations and legacies
3
Other trading activities
4
Investment income
Total
Expenditure
Raising fund
5
Charitable activity
5
Total
Net income/expenditure
Transfers between funds
Net movement in funds
Reconciliation of funds
Total funds brought forward
Total funds carried forward		 Unrestricted
Restricted
2025
2024
£
£
£
£
1,398,309
149,200
1,547,509 1,658,586
151,782
-
151,782
101,550
29,833
-
29,833
22,702
1,579,924
149,200
1,729,124 1,782,838
632,803
373
633,176
584,458
1,028,355
264,336
1,292,691 1,097,796
1,661,158
264,709 1,925,867 1,682,254
(81,234)
(115,509)
(196,743)
100,584
-
-
-
-
(81,234)
(115,509)
(196,743)
100,584
470,402
311,969
782,371
681,787
389,168
196,460
585,628
782,371

All the above amounts relate to continuing activities.

40

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Gynaecology Cancer Research Fund Consolidated and charity Balance Sheet as at 31 December 2025

Notes
2025
2024
£
£
Fixed assets
Intangible fixed assets
14
1,864
2,662
Tangible fixed assets
15
14,365
10,607
Investment
16
7,431
7,431
23,660
20,700
Current assets
Debtors
18
206,273
201,221
Cash at bank and in hand
1,081,311
1,060,129
1,287,584
1,261,350
Creditors: amounts falling due
19
(725,616)
(499,679)
Net current assets
561,968
761,671
Net Assets
585,628
782,371
Funds
Restricted
21
196,460
311,969
Unrestricted
20
389,168
470,402
Total Funds
585,628
782,371
Group		 2025
2024
£
£
1,864
2,662
14,365
10,607
7,432
7,432
23,661
20,701
88,257
157,861
1,055,657
1,029,414
1,143,914
1,187,275
(733,849)
(530,095)
410,065
657,180
433,726
677,881
196,460
311,969
237,266
365,912
433,726
677,881
Charity

As permitted by S408 of the Companies Act 2006, the company has not presented its own income and expenditure and related notes.

These financial statements were approved by the Board of Trustees and authorised for issue on 20 May 2026 and were signed on its behalf by:

Tamara Box, Chair

Company No. 4370087

41

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Gynaecology Cancer Research Fund

Consolidated Statement of Cash Flows for the year ended 31 December 2025

2025 2024
£ £
Cashflow from operating activities
Cash provided by operating activities 2,685 109,820
Cash flows from investing activities
Interest income 29,833 22,702
Purchase of tangible fixed assets (11,336) (1,288)
Net cash used in investing activities 18,497 21,414
Change in cash and cash equivalent in the period 21,182 131,234
Cash and cash equivalents at 1st January, 1,060,129 928,895
Cash and cash equivalents at 31 December, 1,081,311 1,060,129
Reconciliation of net income/(expenditure/ to net cash flow from operating activities:
Net income/(expenditure for the period (196,743) 100,584
Adjustment for:
Investment income (29,833) (22,702)
Depreciation 7,578 8,662
Amortisation 798 799
Decrease/(increase) in debtors (5,052) (10,196)
(Decrease)/increase in creditors 225,937 32,673
Net cash provided by/used in operating activities 2,685 109,820
Analysis of cash and cash equivalent and net debts
Cash in hand and at bank
Opening balance 1,060,129 928,895
Cash flows 21,182 131,234
Closing balance 1,081,311 1,060,129

42

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements For the Year Ended 31 December 2025

1. GENERAL INFORMATION

Company Information

Gynaecology Cancer Research Fund, operating as The Eve Appeal, is a public benefit entity, a charity registered in both England and Wales (registered charity number 1091708) and Scotland (SC0462612) and a company limited by guarantee (company number 04370087), registered in England. The registered office and its principal place of business is The Eve Appeal, 10-18 Union Street, London, SE1 1SZ.

2 ACCOUNTING POLICIES

(a) Basis of Preparation

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these financial statements. The financial statements have been prepared in accordance with the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) including Update Bulletin 2, (Charities SORP (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The Trustees consider that there are no material uncertainties about the group's ability to continue as a going concern.

(b) Going Concern

The Trustees have assessed whether the use of going concern is appropriate and have considered possible events or conditions that might cast significant doubt on the ability of the group to continue as a going concern. The Trustees have given due consideration to the current economic uncertainty and have reduced the risk with income spread across different stream of activity.

Having reviewed forecasts prepared by management the Trustees are confident that the Charity and the group will continue to meet its obligations as they fall due and that therefore the going concern basis continues to be appropriate.

(c) Group Financial Statements

These financial statements consolidate the results of the Charity and its wholly owned subsidiary, The Eve Appeal Limited, on a line-by-line basis. The subsidiary company has the same year end date of 31 December 2025.

(d) Fund Accounting

Unrestricted funds comprise accumulated surpluses and deficits on general funds. They are available for use at the discretion of the Trustees in furtherance of the general charitable objectives.

Designated funds are unrestricted funds which are earmarked for a particular purpose.

e) Income

Income represents amounts receivable by the Charity during the year from all sources. All income is included in the Statement of Financial Activities when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy

43

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements

For the Year Ended 31 December 2025

Legacies are accounted for when the Charity has entitlement, receipt is probable and the amount is measurable. Donations are accounted for on a receivable basis. Other trading activities are accounted for on a receivable basis and in the year to which they relate.

Donated services or facilities are recognised when the Charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the Charity of the item is probable and that economic benefit can be measured reliably.

(f) Expenditure & VAT

Expenditure is accounted for on an accruals basis and is inclusive of irrecoverable VAT. Grants payable are charged to the Statement of Financial Activities when authorised by the Board of Trustees and communicated to the recipient.

Charitable expenditure comprises those costs incurred by the Charity in the delivery of its objectives. It includes both costs that can be allocated directly to such activities and the costs of an indirect nature as necessary to support them.

Costs of raising funds comprise fundraising costs and the costs incurred in the subsidiary trading activities. Fundraising costs include advertising, producing publications, printing and mailing fundraising materials, associated staff costs and an appropriate allocation of support costs.

Support costs are those costs incurred in support of the Charity's primary objectives and are allocated on the basis of staff time spent on those objectives.

Governance costs are those costs relating to compliance with constitutional and statutory requirements and the structure and governance review and are allocated on the basis of time spent overseeing the relevant

(g) Tangible Fixed Assets and Depreciation

Tangible Fixed assets are recorded at cost less depreciation and impairment. Depreciation is provided on all tangible fixed assets in order to write off their cost by equal annual instalments over their expected useful lives. The rate adopted for Fixtures and Fittings @ 25% on cost.

(h) Intangible Fixed Assets and Amortisation

Amortisation is provided on all intangible fixed assets in order to write off their cost by equal annual instalments over their expected useful lives. The rate adopted for trademarks @10% on cost.

(I) Investments

Unlisted investments comprise the following:-

Under the charity SORP this is measured using the equity method of accounting.

The equity method of accounting requires the associate to be initially recognised at its cost (the transaction price paid), including any cost incurred making the investment (transaction costs).

Using the equity method, the carrying amount of an investment in an associate is subsequently adjusted through the SoFA to reflect the investing charity's share of the associate's results. The carrying amount thereby reflects the investor's share of the post acquisition change in the net assets of the associate.

44

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements

For the Year Ended 31 December 2025

(j) Stock

Stock principally consists of artwork donated by artists and is valued at the lower of cost and net realisable value. Artworks provided by artists are recognised in the financial statements at their anticipated sales price, less anticipated cost of sales and any subsequent impairment.

(k) Cash and cash equivalents

Cash at bank and in hand includes deposits which can be withdrawn within 24 hours without penalty and short-term deposits which have a maturity period of 3 months or less and are not subject to significant risk of changes in value.

(I) Tax Status

Gynaecology Cancer Research Fund (Limited by Guarantee) is a registered company, number 04370087 and is exempt from corporation tax under the provisions of Sections 466-493 of the Corporation Taxes Act 2010.

(m) Operating Leases

Rentals payable under operating leases are charged to the Statement of Financial Activities as incurred over the period of the lease on a straight-line basis.

(n) Pensions

The Charity operates a defined contribution pension scheme. The contributions to the defined contribution scheme are charged to the Statement of Financial Activities as they become payable.

(o) Financial Instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value. The Charity does not have any bank loans.

(p) Significant Accounting Estimates and Judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances:

(i) Gifts In kind

Gifts in kinds are recognised within incoming resources and expenditure at an estimate of the value to the Charity of the donated services or goods. Where possible the value of services/goods are confirmed directly with the supplier however in some instances this information is not available and a best estimated is made of the expected cost of such goods based on what the Charity would be willing to pay for similar services or goods at a market rate.

(ii) Grant creditors

In the year ended 30/06/2019 year the Trustees considered the treatment of the recognition of grant creditors falling due within one year and after one year and have adopted a better estimation of creditors falling due within one year.

45

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements for the year ended 31 December 2025

3. Income: donations and legacies

Individual giving
Community
Trust and foundations
Major donors
Corporate
Legacies
Gifts in kind
Total		 2024
Unrestricted Restricted
Total
£
£
£
£
327,038
7,669
334,707
350,144
384,308
13,660
397,968
402,501
36,666
86,851
123,517
323,002
61,002
11,020
72,022
86,774
214,762
30,000
244,762
236,527
5,768
-
5,768
68,866
368,765
-
368,765
190,772
1,398,309
149,200
1,547,509
1,658,586
2025

In 2025, £1,398,309 (2024: £1,231,010) of donation and legacies related to unrestricted funds and £149,200 (2024: £427,576) was attributable to restricted funds. Income from donation and legacies include donated services worth £368,765 (2024: £190,772).

4. Income: from trading activities

Trading subsidiary (see note 17)
Total		 2024
Unrestricted Restricted
Total
£
£
£
£
151,782
-
151,782
101,550
151,782
151,782
101,550
2025

46

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements for the year ended 31 December 2025

5. Analysis of expenditure

5. Analysis of expenditure
Expenditure on raising funds (Note 6)
Expenditure on charitable activities (Note 7, 8 & 9)
Charity expenditure on raising funds
Consolidated
Expenditure on raising funds (Note 6 )
Expenditure on charitable activities (Note 7, 8 & 9)
Charity expenditure on raising funds
Consolidated		 Direct costs
Support
costs
Governance
cost
Total
2025
£
£
£
£
537,098
78,479
17,598
633,175
1,096,539
160,224
35,929
1,292,692
1,633,637
238,703
53,527 1,925,867
1,633,637
238,703
53,527 1,925,867
Direct costs
Support
costs
Governance
cost
Total
2024
£
£
£
£
458,128
96,970
29,360
584,458
960,614
105,299
31,882
1,097,795
1,418,742
202,269
61,242
1,682,253
1,418,742
202,269
61,242
1,682,253

Expenditure relating to raising funds in 2025 was £633,548 unrestricted (2024: £584,374) and £373 restricted (£2024: £84). Expenditure on charitable activities in 2025 was £1,028,355 unrestricted (2024: £662,812) including donated services worth £368,765 (2024: £190,772). All donated services are clasified as unrestricted.

6. Direct cost of generating donations and legacies

Individual giving
Community
Trust and foundations
Major donors
Corporate
Digital engagement
Central
Total		 2024
Unrestricted
Restricted
Total
£
£
£
£
44,596
373
44,969
46,918
68,383
-
68,383
89,482
-
-
-
469
2,738
-
2,738
4,152
31,344
-
31,344
12,937
10,858
-
10,858
-
378,806
-
378,806
304,170
2025
536,725
373
537,098
458,128

47

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements for the year ended 31 December 2025

7. Direct costs of charitable activities

Research grants (note 10)
Ask Eve - Nurse-led information service
Ask Eve Assist - AI Chatbot
Early Women Promise
Information and awareness
Outreach
Research
Gifts in kind
Total		 2024
Unrestricted
Restricted
Total
£
£
£
£
169,917
73,094
243,011
234,202
41,593
23,687
65,280
75,770
231
41,714
41,945
-
2,515
54,093
56,608
154,698
155,921
46,648
202,569
225,838
28,858
19,044
47,902
17,262
70,459
-
70,459
62,073
368,765
-
368,765
190,772
838,259
258,280
1,096,539
960,615
2025

8. Direct costs of governance

Group - audit fees
Group - non audit fees
Directors indemenity insurance
Trustee costs
Staff and contractor costs
Other costs
Total		 2024
Unrestricted
Restricted
Total
£
£
£
£
20,003
-
20,003
17,256
2,237
-
2,237
6,832
1,466
-
1,466
2,869
-
77
29,821
-
29,821
33,785
-
-
-
423
53,527
-
53,527
61,242
2025

48

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements for the year ended 31 December 2025

9. Analysis of support costs

Rent, service charges and utilities
Insurance
IT, phone, and internet
Staff and contractor costs
General corporate services
Total		 2024
Unrestricted Restricted
Total
£
£
£
£
13,389
1,400
14,789
15,684
2,022
-
2,022
423
11,032
-
11,032
34,286
179,643
4,656
184,299
106,695
26,561
-
26,561
45,181
232,647
6,056
238,703
202,269
2025

10. Research grants awarded by institution

Included in Charitable Activities were the following research grants:

2025 2024
Unrestricted Restricted Total
£ £ £ £
University College London - Strategic Support 39,000 1,000 40,000 40,000
University of Edinburgh - Ovarian Cancer - 56,051 56,051 56,126
University of Manchester - Endometrial Tumors 59,862 59,862
University of Manchester - Endometrial
Cancer 26,084 - 26,084 -
Small Grants:
University College London - Nevigate BRCA 9,990 9,990
University College London - BRCA 1 & 2 carrier 12,866 6,053 18,919
University of Southampton - BRCA Carriers 11,749 11,749
Imperial College London - BRCA 1 & 2
associated STIC Lesions 15,356 15,356
AMRC Fellowship - - 44,249
Rare Gynae - - - 90,948
British Gynaecological Cancer Society Audit 5,000 - 5,000 5,000
Grant commitments reclaimed - - - (2,121)
Total 169,917 73,094 243,011 234,202

BRCA = Breast Cancer gene.

BRCA1 and BRCA2 are two genes that play a crucial role in DNA repair and are associated with an increased risk of several cancers, particularly breast and ovarian cancer.

British Gynaecology Cancer Society (BGCS) Audit.

49

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements for the year ended 31 December 2025

  1. Staff costs
Wages and salaries
Social security costs
Staff pension
Costs of contracts
Total staff costs		 2025
2024
£
£
711,141
718,591
80,947
70,230
38,128
31,697
830,216
820,518
30,897
44,937
861,113
865,455

Total number of employees whose total employees benefits (excluding employer pension costs and employer national insurance contributions) amounted to over £60,000 in the year were:

£70,000 - £79,999
£80,000 - £89,999
£90,000 - £99,999
Average staff numbers:
Charitable activities
Fundraising and support		 2025
2024
1
1
-
-
1
1
8
10
9
8
17
18

The key management personnel of the parent charity comprises the Chief Executive, the Director of Fundraising, the Head of Programmes and the Head of Finance. The total employee benefit of the key management personnel in the year were £344,062 (2024: £309,683).

  1. Trustees remuneration and expenses of benefits in kind

None of the Trustees received any remuneration during the year (2024: None).

During the year £1,466 (2024: £2,689) was paid in respect of trustees indemnity insurance. No Trustees claimed for any expenses during the year (2024: none).

13. Net movement in funds

13. Net movement in funds
2025 2024
£ £
Net movement in funds is stated after charging:
Auditors remuneration - current year 20,003 17,256
Amortisation 798 799
Depreciation 7,578 8,662
Amounts payable under operating leases:
Land and buildings 27,758 38,433

50

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements for the year ended 31 December 2025

14. Intangible fixed assets - Group and Charity

14. Intangible fixed assets - Group and Charity
Cost at 1 January 2025
Amortisation:
At 1 January 2025
Charge for the year
At 31 December 2025
Net book value at 31 December 2025
Net book value at 31 December 2024
15. Tangible fixed assets
Cost:
At 1 January 2025
Additions
Disposal
At 31 December 2025
Depreciation:
At 1 January 2025
Charge for the year
Depreciation on disposals
At 31 December 2025
Net book value at 31 December 2025
Net book value at 31 December 2024		 Trademarks
£
7,988
5,326
798
6,124
1,864
2,662
Fitting &
Equipment
£
33,450
11,336
-
44,786
22,843
7,578
-
30,421
14,365
10,607

51

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements for the year ended 31 December 2025

  1. Investments held as fixed assets - charity
Shares in subsidiary undertaking at cost
Shares in Joint Venture at fair value		 2025
2024
£
£
1
1
7,431
7,431
7,432
7,432

Joint Venture

The charity has a share in Sole Diagnostics GmBh, an Austrain company. Shares (which will decrease over time) were gifted to the Charity from Professor Martin Winschwendter.

The carrying amount of the investment was £7,431 at the year end, which is deemed to be its fair value.

17. Subsidiary

The charity has wholly owned subsidiary incorporated in England, Eve Appeal Limited, which raises funds through actvitiy including cause related marketing and sales of goods. The company pays its profit under Gift Aid to the Gynaecological Cancer Research Fund.

A summary of its trading results (included with "Other trading activities") for the period ended 31 December 2025 is as follows:

Profit and loss
Turnover
Administration expenses
Net profit before tax
Taxation
Net result
Profit and loss reserves
Brought forward at 1st January
Net result in period
Distribution to Gynaecology Cancer Reseach Fund
Summary Balance Sheet
Current assets
Debtors
Cash at bank and in hand
Total current assets
Current liabilities
Creditors - amounts falling due within one year
Net current assets
Total assets less total liabilities
Capital and reserves
Share captial
Profit and loss accounts
Total		 2025
2024
£
£
151,782
101,550
120
2,940
151,902
104,490
-
-
151,902
104,490
104,490
85,631
151,902
104,490
(104,490)
(85,631)
151,902
104,490
129,567
74,845
25,654
30,715
155,221
105,560
(3,318)
(1,069)
151,903
104,491
151,903
104,491
1
1
151,902
104,490
151,903
104,491

52

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements for the year ended 31 December 2025

18. Debtors
Group Charity
2025 2024 2025 2024
£ £ £ £
Trade debtors 149,025 65,696 31,008 22,337
Prepayment and accrued income 54,369 133,053 54,369 133,053
Other debtors 2,879 2,472 2,880 2,471
206,273 201,221 88,257 157,861
19. Creditors
Group Charity
2025 2024 2025 2024
£ £ £ £
Grants payable 629,787 447,286 629,787 447,286
Trade creditors 28,636 16,363 28,636 9,625
Amount owed to group undertakings - - 11,297 38,223
Accruals 23,321 25,888 20,003 24,820
Taxation and social security 2,625 1,251 2,625 1,250
Other creditors 41,247 8,891 41,501 8,891
725,616 499,679 733,849 530,095
20. Unrestricted funds - Group
At 1 Income Expenditure Transfers At 31
January December
2025 2025
£ £ £ £ £
General funds 290,402 1,579,924 (1,661,158) (20,000) 189,168
Emergency fund 180,000 - - 20,000 200,000
470,402 1,579,924 (1,661,158) - 389,168

Emergency fund

The reserves policy for the charity, as agreed by the Trustess, is to maintain a minimum of three months budgeted expenditure, excluding expenditure on research grants. Further information on this and the rationale for this can be found in the reserves section of the Trustees Report.

Unrestricted funds - Charity

General funds
Emergency fund		 At 1
January
2025
Income
Expenditure
Transfers
At 31
December
2025
£
£
£
£
£
185,912
1,532,632
(1,661,278)
(20,000)
37,266
180,000
-
-
20,000
200,000
365,912
1,532,632
(1,661,278)
-
237,266

53

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements for the year ended 31 December 2025

20. Restricted funds - Group
Ask Eve
Ask Eve Assist - AI Chatbot
Womb Cancer
BRCA Research
Vulval Cancer
Awareness
HPV Resources
Rare Gynaecology Research
Ovarian Cancer Research
UCL Strategic Research Funding
Everly Women Promise
Outreach (funded by Gilead)
Outreach (funded by Seven Stones)
Bloomer Fund
Cervical Cancer Prevention Week
Ask Eve (funded by Peter Stabbings)
Fellowship		 At 1 January
2025
Income
Expenditure
Transfers
At 31
December
2025
£
£
£
£
£
22,070
32,164
(25,005)
-
29,229
30,000
46,945
(43,858)
-
33,087
-
379
-
-
379
16,044
-
(16,044)
-
-
1,445
-
-
-
1,445
79,410
167
(46,597)
-
32,980
678
-
-
678
1
18,298
(373)
-
17,926
103,176
300
(56,051)
-
47,425
1,000
-
(1,000)
-
-
56,760
-
(56,760)
-
-
1,325
-
(1,325)
-
-
-
20,000
(17,769)
-
2,231
-
11,020
-
-
11,020
-
10,000
-
-
10,000
-
10,000
-
-
10,000
60
-
-
60
311,969
149,273
(264,782)
-
196,460

Restricted Funds:

Ask Eve: The nurse let information service providing free, confidential, gynae information via phone or email.

Ask Eve Assist (AI Chatbot): This services is designed to assist with simple gynaecological questions, allowing trained nurses focus on more complex support.

Womb: The most common gynaecological cancer in the UK, with around 10,000–11,000 women diagnosed each year and incidence having increased significantly over recent decades. In response to donor requests to prioritise research in this area, restricted funds have been established to support targeted studies aimed at improving early detection, screening, prevention and understanding inherited risk, as well as supporting outreach and awareness initiatives.

BRCA Research: Several of our research programmes have a strong focus on the BRCA gene mutation to early detect or prevent ovarian and breast cancer - for example BRAC Project, BRCA UNITE and GCaPPS.

Vulval cancer: A rarer gynaecological cancer, with around 1,500 women diagnosed in the UK each year, but incidence has been rising over time. Following donor interest in advancing research in this underfunded area, restricted funds have been created to drive progress in increasing our understanding, and focusing research efforts on early detection and prevention.

Awareness: This fund is restricted to raising awareness of gynaecological cancers and communication work around certain campaigns such as Get Bleeding Checked.

HPV Resources: This project works to embed a deeper and more nuanced public understanding of HPV, seeing to reduce disease risk, promote preventative behavioural change, and improve patient outcomes for HPV and related disease across the board.

Rare Gynaecological Cancer Research: Less than 5% of the 21,000 women diagnosed with gynaecological cancer in the UK are diagnosed with the rate form. The low number of new cases of these rare cancers mean individual doctors are unfamiliar with symptoms, too often resulting in a late diagnosis, with treatment that may not be optimal for the disease type and subsequent progression of the disease. More research to advance and improve the early diagnosis and prevention rare gynaecological cancers.

54

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Gynaecology Cancer Research Fund Notes to the Financial Statements for the year ended 31 December 2025

Ovarian Cancer Research: In the UK nearly 7,500 people are diagnosed with ovarian cancer every year. The symptoms are not always obvious, and it is often diagnosed in a late state, Research into early detection, risk prediction and prevention is needed.

UCL Strategic Research Funding: Focusing on Prof. Widschwendter's research continuing at UCL. The Clinical Assessment & work up of the WIDqEC test in women at hight risk for Endometrial (Womb) Cancer.

Everly Women Promise: This project supports and educates women in the workplace, to report symptoms and seeks advice on gynaecological health issues and makes employers aware of the issues. The aim is to both improve the health chances for each women but to improve to corporate environment, through engagement at a corporate ownership and management level.

Outreach: This project addressed the disparities in gynaecological health outcomes among Black women by improving awareness, access to information, and confidence in seeking medical care for gynae cancers and overall health. This funding enabled us to deliver tailored education, develop new partnerships, and create sustainable resources that will benefit communities beyond the initial grant period.

The Bloomer Fund: has been set up in memory of Jonathan and Judy Bloomer (long-time supporters of the charity and Judy served as a Trustee). All money in this fund is restricted to research.

Cervical Cancer Prevention Week: to run a campaign promoting the tipes/adaptation to help make cervical screening easier. This includes coverage through TV, newspapers, radio and online digital channels.

Fellowship: With limited funding, and uncertain pathways, the challenges for researchers working in gynaecological cancer are numerous. The Eve Appeal is continuing our legacy of investing in the next generation of gynaecological cancer research stars through a fellowship scheme. The aim was to attract and retain researchers in the field, by providing substantial financial assistance, resources, and a network of support. This initiative is cofunded with North West Cancer Research

55

Docusign Envelope ID: 0AD6DB94-9313-8DC3-8197-981448A3CEB6

Gynaecology Cancer Research Fund

Annual Report incorporating a Directors’ Report and Accounts for the year ending 31 December 2025

Notes to the Financial Statements for the year ended 31 December 2025

22. Analysis of Net Assets between Funds - Group

Fixed Assets
Current Assets
Creditors: amounts falling due within 1 year
Total		 2024
Unrestricted
Restricted
Total
£
£
£
£
23,660
-
23,660
20,700
1,091,124
196,460 1,287,584
1,261,350
(725,616)
-
(725,616)
(499,679)
389,168
196,460
585,628
782,371
2025

23. Legal Status of the Charity

The charity is limited by guarantee and therefore does not have share capital. The liability of the members is limited to the sum of £1 per member, and the number of members was 11 (2024:13).

24. Ultimate Controlling Party

Eve Appeal Limited is a wholly owned subsidiary of Gynaecology Cancer Research Fund, which is the ultimate controlling party. The ultimate controlling party of Gynaecology Cancer Research Fund are the Trustees.

25. Related Party Transactions

During the year under review, the charity received income totalling £14,550 in donations from 9 Trustees, both current and resigned in the period, including partners (2024: £18,070 from 9 Trustees including partners).

Reed Smith LLP provided pro bono legal services and other support to the charity totalling £50,113 (2024: 80,116). Tamara Box, a partner at Reed Smith LLP is also chair of board of trustee of the charity.

26. Commitments under operating leases

The group and charity had the following future minimum lease payment under non-cancellable operating leases:

Land and buildings:
Within one year
Between one year and five years
After five years
Equipment
Within one year
Between one year and five years
Total Commitments		 2025
2024
2025
2024
£
£
£
£
10,675
10,675
10,675
10,675
14,682
25,357
14,682
25,357
25,357
36,032
25,357
36,032
840
840
840
840
721
1,561
721
1,561
1,561
2,401
1,561
2,401
26,918
38,433
26,918
38,433
Group
Charity

56